Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin

Table 1 Toxicity observation II

	Ad-hEndo+ cisplatin	Ad-hEndo	cisplatin	Ad-null	NS
White blood cell (×10³/mm³)	7.58 ± 2.12	7.89 ± 2.5	7.44 ± 1.98	7.96 ± 2.58	8.02 ± 2.83
Red blood cell (×10⁴/mm³)	701.5 ± 28.5	721.3 ± 22.5	700.4 ± 20.2	756 ± 25.2	780.5 ± 25.5
Platelet (×10⁴/mm3)	30.2 ± 7.5	25 ± 8.2	22.5 ± 6.9	32 ± 8.9	41 ± 7.2
GOT (IU/I)	241.3 ± 26.8	219.6 ± 35.6	252.6 ± 29.7	240.5 ± 39.4	267.5 ± 36.6
GPT (IU/I)	50.2 ± 11.3	43.2 ± 7.5	40.5 ± 7.9	42.8 ± 7.4	45.2 ± 8.4

Mean ± SD of 5 mice in each group. Compared with the control groups(p > 0.05), all treatment groups showed no significant difference.

ISSN: 1756-9966